{"entity":{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","aka":[],"tldr":"A phase 1/2 trial of cetuximab, nab-paclitaxel, gemcitabine, fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.","summary":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation is a phase 1/2, interventional study registered as NCT07678593 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 222 participants, started 2026-09 and due to reach its primary completion in 2027-11. Interventions recorded: GFH276; Cetuximab; Nab paclitaxel; Gemcitabine; Fluorouracil; Leucovorin; Irinotecan; Oxaliplatin. Conditions listed: Advanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma; RAS Mutation. Primary outcome: Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) Events; Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE); Phase II:Objective Response Rate (ORR). Sites: Australia, China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07678593","url":"https://clinicaltrials.gov/study/NCT07678593"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["cetuximab","nab-paclitaxel","gemcitabine","fluorouracil","flot","folfiri","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07678593","phase":"1/2","setting":"A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","enrolled":222,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07678593/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}